Viewing data from:

NIKKI

ANDA

DROSPIRENONE; ETHINYL ESTRADIOL | A201661 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: YAZ(TE code: AB)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Bayer Schering Pharma AG et al v. Lupin Ltd et al 2:2010cv01166 ANDA 201661drospirenone and ethinylestradiol	D. Nev.	2010-07-15	Terminated 2013-11-27	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.1895

per ea

Lowest NADAC/Unit

$0.1895

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68180088673NIKKI 3 MG-0.02 MG TABLET	$0.1895	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Nikki (2024)

Total Spending

$129K

Total Claims

3,369

Beneficiaries

1,045

Avg Cost/Unit

$0.65

Spending Trend

$197K(2019)→$198K(2020)→$199K(2021)→$210K(2022)→$172K(2023)→$129K(2024)

YoY Change:-28.0%

5yr CAGR:-15.8%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Products (1)

#001 — 3MG;0.02MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 27, 2014

No patent or exclusivity listings for this strength.